article thumbnail

Rashedi Hassan takes over Sales & Marketing management of Telstar’s subsidiary in Bangladesh

Pharma Mirror

Azbil Telstar announces the appointment of Rashedi Hassan as a Sales & Marketing Manager of the subsidiary of the company in Dhaka, Bangladesh. The post Rashedi Hassan takes over Sales & Marketing management of Telstar’s subsidiary in Bangladesh appeared first on Pharma Mirror Magazine. With more than 18.

Sales 246
article thumbnail

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Pharmaceutical Technology

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Moderna cuts sales forecasts for its COVID-19 vaccine

Bio Pharma Dive

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.

Sales 301
article thumbnail

US plans shift to private market sales of COVID-19 vaccines, drugs

Bio Pharma Dive

The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.

Sales 274
article thumbnail

Aerie’s glaucoma drug journey ends in $770M sale to Alcon

Bio Pharma Dive

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 284
article thumbnail

Lilly market value soars on higher sales, obesity drug potential

Bio Pharma Dive

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246
article thumbnail

Novartis sales of Zolgensma gene therapy slow as market shifts

Bio Pharma Dive

Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.